


# Ecology and evolution of the Cystic Fibrosis lung microbiome




**Heather Maughan<sup>1</sup>, Yunchen Gong<sup>2</sup>, Pauline Fung<sup>2</sup>, Pauline Wang<sup>2</sup>,  
David M. Hwang<sup>3</sup>, David S. Guttman<sup>1,2</sup>**

<sup>1</sup>Cell & Systems Biology


<sup>2</sup>Centre for Analysis of Genome Evolution and Function

<sup>3</sup>University Health Network  
University of Toronto


# Cystic Fibrosis and lung airways




Lung showing bronchus



# Cystic Fibrosis and lung airways




Lung showing bronchus



# Multiple microbes inhabit CF lungs

*Pseudomonas aeruginosa*




<http://medicalsciences.wordpress.com/2009/09/07/infectious-disease-nosocomial-pathogens/>

*Burkholderia* spp.



<http://www.getor.4t.com/concurso/bacteriologia/burkholderiafacieapical.jpg>

*Staphylococcus aureus*




<http://www.healthype.com/staphylococcus-aureus.html>

*Stenotrophomonas maltophilia*



ASM MicroLibrary.org © Buxton  
<http://www.microbelibrary.org/microbelibrary/11165/czimages/Articleimages/Atlas-Mac/Stenotrophomonas%20maltophilia%20fig20.jpg>

*Haemophilus influenzae*




<http://www.nhs.uk/conditions/Hib/pages/introduction.aspx>

*Aspergillus*



Known from culturing and some molecular characterization

# Microbial abundances are dynamic



- Determine how abundances are influenced by clinical treatments
- Identify genes encoding clinically relevant traits (e.g., antibiotic resistance)
- Determine how species interactions influence disease progression

# Study



- Longitudinal sampling of sputum and lung explant specimens
  - 15 lung explants per year
  - 3-4 sputum samples from 600 adult and child patients per year
- Characterize diversity of bacterial and fungal communities
  - baseline lung function and acute pulmonary exacerbations
- Characterize fine scale population diversity in major pathogens (*P. aeruginosa*, *Aspergillus*)
- Characterize antibiotic resistance potential of microbial community
- Characterize metabolic potential of microbial community (metatranscriptomics)

# Study

- Longitudinal sampling of sputum and lung explant specimens
  - 15 lung explants per year
  - 3-4 sputum samples from 600 adult and child patients per year
- Characterize diversity of bacterial and fungal communities
  - baseline lung function and acute pulmonary exacerbations
- Characterize fine scale population diversity in major pathogens (*P. aeruginosa*, *Aspergillus*)
- Characterize antibiotic resistance potential of microbial community
- Characterize metabolic potential of microbial community (metatranscriptomics)

# Workflow of 16S rDNA targeted sequencing

- Targeted sequencing of 16S rDNA hypervariable regions




Up to eight samples can be loaded onto the flow cell for simultaneous analysis on the Illumina Genome Analyzer.

8 lanes per run



## Whole community DNA sequencing




- Classification of reads using RDP Classifier (Wang et al. 2007)
- Comparison between communities
- Associations between community composition and disease




# Metagenomic Analysis by Serial Illumina Sequencing

MASIS: targeted sequencing of V5, V6, and V7 hypervariable regions




**8x multiplexing = 64 patient samples per Illumina GAIIx run**

# Classification of sequence reads



# Information content provided by MASIS



# Testing MASIS with known templates

## Controls


- one known species, total read length = 114bp (36bp × 4)
- laboratory mixed community

Total Reads	Quality cutoff	Quality Reads	Percent Quality	False positive %
17,520,529	5 sites < 30	13,530,371	77%	0.08%
17,520,529	2 sites < 30	9,281,166	53%	0.06%
17,520,529	2 sites < 33	983,819	6%	0.02%
17,520,529	2 sites < 35	45,709	0.3%	0.006%

# Characterizing CF bacterial communities

Sample	#reads	#reads to genus (%)
629	8,560	3,975 (46%)
R28148	9,926	4,321 (44%)
Sputum2	17,025	14,949 (88%)
647SE	20,510	8,216 (40%)
D72112	27,036	10,435 (39%)
545	61,854	59,349 (96%)
Sputum2Q	77,055	64,219 (83%)
10-Aug	84,625	82,766 (98%)
D71775	105,668	18,332 (17%)
590	110,307	75,229 (68%)
712	131,375	72,344 (55%)
D71277	295,908	292,933 (99%)

# CF samples differ in their bacterial diversities





# Summary & Future Work

- New MASIS method produces billions of reads per run and sufficient sequence for taxonomic resolution to at least genus level
- Preliminary deep sequencing of CF samples reveals large differences between patients in bacterial community diversity
- Continue 16S targeted sequencing of control communities and more CF samples
- Metatranscriptome sequencing and metabolic reconstruction
- Associations of community composition and function with disease progression

# Acknowledgements

## THE GUTTMAN LAB

Ryan Austin  
Heath O'Brien  
Amy Lee  
Honour McCann  
Jennifer Lewis  
Jessica Yang  
Carmen Yea  
Kamran Rizzolo  
Shalabh Thakur  
Craig Diegel



Lijie Yuan  
Jianfeng Zhang  
Joan Ouellette



National  
Sanitarium  
Association



Cystic Fibrosis  
Canada

*Breathing life into the future®*



CIHR IRSC  
Canadian Institutes of Health Research  
Instituts de recherche en santé du Canada